Kriegmaier 2002.

Study characteristics
Methods	randomized, phase III multicenter (8 centers)/Austria, Germany
Participants	Study setting primary and recurrent Eligibility criteria patients suspicious for primary BCa or tumor recurrence Non‐eligibility criteria NR Intervention cohort participants recruited: 83 unifocal/multifocal tumors: NR Comparator cohort participants recruited: n = 82 unifocal/multifocal tumors: NR
Interventions	Intervention: PDD‐TURBT Comparator: WL‐TURBT Adjuvant instillation therapy: NA
Outcomes	Outcome(s) residual tumor detection rate Results median follow‐up: 2 weeks RFS rate was 67.3% in intervention group vs 46.9% in comparator group (P < 0.031)
Funding sources	NR
Declarations of interest	NR
Contact of study author	Date of contact attempt to first study author: 30 November 2020 Contact status: no reply to date
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "the randomization procedure was stratified according to participating centers and further by the potentially prognostically relevant risk score, defined according to the results of European Organization for the Research and Treatment of Cancer studies 30831, 30790 and 30782 as 1—recurrence, 2—early recurrence at less than 12 months, 3—bacillus Calmette‐Guerin therapy less than 12 months in duration and 4—a history of carcinoma in situ" Comment: method of sequence generation unclear
Allocation concealment (selection bias)	Unclear risk	Quote: "the randomization procedure was stratified according to participating centers and further by the potentially prognostically relevant risk score, defined according to the results of European Organization for the Research and Treatment of Cancer studies 30831, 30790 and 30782 as 1—recurrence, 2—early recurrence at less than 12 months, 3—bacillus Calmette‐Guerin therapy less than 12 months in duration and 4—a history of carcinoma in situ" Comment: allocation concealment unclear
Blinding of participants and personnel (performance bias) Surgeon	High risk	Quote: NA Comment: surgeon unblinded
Blinding of participants and personnel (performance bias) Participants/study personnel	Unclear risk	Quote: NA Comment: unclear whether study participants and other study personnel were blinded
Blinding of outcome assessment (detection bias) Subjective outcomes (all outcomes)	Unclear risk	Quote: NA Comment: unclear whether study personnel were blinded
Incomplete outcome data (attrition bias) Oncological outcomes	High risk	Quote: NA Comment: loss to follow‐up was > 20%
Selective reporting (reporting bias)	Unclear risk	Quote: NA Comment: no protocol available
Other bias	Low risk	Quote: NA Comment: no other bias identified